Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Lymphoma 2Ovarian Neoplasms 1Neoplasms 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1

Interventions

romidepsin 12Cyclophosphamide 11Vincristine 9Rituximab 9Etoposide 9Lenalidomide 8Doxorubicin 8Brentuximab Vedotin 8fludarabine 6Prednisone 6Peripheral Blood Stem Cell Transplantation 6Melphalan 6Depsipeptides 6fludarabine phosphate 5Mycophenolic Acid 5Lactones 5Gemcitabine 5Cytarabine 5Bendamustine Hydrochloride 5Antilymphocyte Serum 5Whole-Body Irradiation 4Tacrolimus 4Sirolimus 4Methotrexate 4MLN 8237 4Carmustine 4Bortezomib 410-propargyl-10-deazaaminopterin 4thymoglobulin 3duvelisib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Lymphoma, T-Cell × quisinostat × Clear all
NCT01486277 2016-11-03

A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma

Janssen Research & Development, LLC

Phase 2 Completed
26 enrolled
DermatologicLymphoid

Lymphoma, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡